2023
COVID‐19 mRNA vaccine, but not a viral vector‐based vaccine, promotes neutralizing anti‐type I interferon autoantibody production in a small group of healthy individuals
Xu W, Wen X, Cong X, Jiang W. COVID‐19 mRNA vaccine, but not a viral vector‐based vaccine, promotes neutralizing anti‐type I interferon autoantibody production in a small group of healthy individuals. Journal Of Medical Virology 2023, 95: e29137. PMID: 37792386, PMCID: PMC10603818, DOI: 10.1002/jmv.29137.Peer-Reviewed Original ResearchConceptsViral vector-based vaccinesCOVID-19 mRNA vaccinesVector-based vaccinesGroup of healthy individualsMRNA vaccinesHealthy individualsPlasma levelsAnti-type I IFN autoantibodiesI interferonLevels of IgG autoantibodiesEvaluate plasma levelsHuman self-antigensPost-COVID-19 vaccinationCOVID-19 vaccineImpaired immune defenseInduce adverse eventsBaseline in vitroIncreased antibody levelsSARS-CoV-2 infectionSARS-CoV-2 antigensType I IFNType I interferonAutoantibody productionSelf-antigensInduce autoimmunity
2022
COVID‐19 is associated with bystander polyclonal autoreactive B cell activation as reflected by a broad autoantibody production, but none is linked to disease severity
Jiang W, Johnson D, Adekunle R, Heather H, Xu W, Cong X, Wu X, Fan H, Andersson L, Robertson J, Gisslén M. COVID‐19 is associated with bystander polyclonal autoreactive B cell activation as reflected by a broad autoantibody production, but none is linked to disease severity. Journal Of Medical Virology 2022, 95: 10.1002/jmv.28134. PMID: 36086941, PMCID: PMC9538121, DOI: 10.1002/jmv.28134.Peer-Reviewed Original ResearchConceptsAssociated with mild disease outcomeAutoreactive B cell activationMild disease outcomePlasma levels of IgGB cell activationLevels of IgGPlasma levelsAutoantibody productionAnti-type I IFN autoantibodiesPatient groupAssociated with autoimmune featuresLong-term humoral immunityDisease outcomeDisease severityLife-threatening COVID-19Antibody protein arraysHuman coronavirus (HCoV)-229ESeverity of COVID-19Nonpathogenic autoantibodiesAutoantibody levelsSpike proteinAutoimmune featuresSelf-antigensAutoreactive IgGHumoral immunityCOVID-19 mRNA vaccine BNT162b2 induces autoantibodies against type I interferons in a healthy woman
Ning W, Xu W, Cong X, Fan H, Gilkeson G, Wu X, Hughes H, Jiang W. COVID-19 mRNA vaccine BNT162b2 induces autoantibodies against type I interferons in a healthy woman. Journal Of Autoimmunity 2022, 132: 102896. PMID: 36029717, PMCID: PMC9385769, DOI: 10.1016/j.jaut.2022.102896.Peer-Reviewed Original ResearchConceptsType I interferonHealthy womenI interferonAutoantibody productionPre-vaccinationAssociated with COVID-19 disease severityBetamethasone dipropionate ointmentMRNA vaccine BNT162b2Human PBMCs in vitroPBMCs in vitroDose of vaccineImmune response to infectious diseasesCOVID-19 disease severityType I IFNResponse to type I IFNsAutoimmune featuresNeutralizing autoantibodiesVaccine BNT162b2Case reportChronic disease pathogenesisInduce autoantibodiesClinical manifestationsAutoimmune responsePlasma levelsResponse to infectious diseases